1
|
Peng J, Ma P, Wu X, Yang T, Hu Y, Xu Y, Li S, Zhang H, Liu H. A case-control study and systematic review of the association between glutathione S-transferase genes and chronic kidney disease. Heliyon 2023; 9:e21183. [PMID: 37920524 PMCID: PMC10618768 DOI: 10.1016/j.heliyon.2023.e21183] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 09/10/2023] [Accepted: 10/18/2023] [Indexed: 11/04/2023] Open
Abstract
Background GSTM1 deletion was reported to be associated with CKD progression in cohort studies. However, the results of case‒control studies were conflicting. The association between GST genes and CKD progression needs to be studied in China. Therefore, we conducted this case‒control study and systematic review for Southwest China to outline the association between GST genes and CKD. Methods CKD patients and healthy controls were enrolled from June 1, 2022 to 1 August 2022. Reported case‒control studies were identified by searching databases until 1 September 2022 for meta-analysis. Results Significant associations were found between deletions of GSTM1 and GSTT1 and CKD risk (all P < 0.01) but not in GSTP1 rs1695 (all P > 0.05) in Southwest China. Then, we conducted a meta-analysis on 30 studies and found positive associations between deletions of GSTM1 and GSTT1 and CKD risk (all P < 0.01) but failed to find associations in GSTP1 rs1695 (all P > 0.05). Stratification analysis for ethnicity only showed a significant association in Southern Asia (P < 0.05) but not in Eastern Asia or other populations. This was different from our case‒control results. The current evidence was influenced by study quality and PCR method but not by control selection. Given the different stages of CKD patients, a subanalysis of disease stages was performed, and the results remained positive. Interestingly, we found no significant associations between DM-CKD and GST genes, which should be interpreted with caution. Conclusion We found that GSTM1 and GSTT1 null genotypes were risk factors for CKD in China. The results of the meta-analysis were somewhat different from our results. We considered that antioxidant therapy might be useful for the treatment of these patients.
Collapse
Affiliation(s)
- Jie Peng
- School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, 783# Xindu Avenue, Chengdu, Sichuan Province, 610500, PR China
| | - Pei Ma
- Department of Forensic Medicine, Zhongnan Hospital, Wuhan University, 168# Donghu Road, Wuhan, Hubei Province, 430071, PR China
- Center for Gene Diagnosis, Zhongnan Hospital, Wuhan University, 168# Donghu Road, Wuhan, Hubei Province, 430071, PR China
| | - Xueqin Wu
- School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, 783# Xindu Avenue, Chengdu, Sichuan Province, 610500, PR China
| | - Tianrong Yang
- School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, 783# Xindu Avenue, Chengdu, Sichuan Province, 610500, PR China
| | - Yuting Hu
- School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, 783# Xindu Avenue, Chengdu, Sichuan Province, 610500, PR China
| | - Ying Xu
- School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, 783# Xindu Avenue, Chengdu, Sichuan Province, 610500, PR China
| | - Shuang Li
- Department of Clinical Laboratory, The Third People's Hospital of Chengdu, 82# Qinglong Street, Chengdu, Sichuan Province, 610014, PR China
| | - Hang Zhang
- Department of Clinical Laboratory, The Third People's Hospital of Chengdu, 82# Qinglong Street, Chengdu, Sichuan Province, 610014, PR China
| | - Hongzhou Liu
- School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, 783# Xindu Avenue, Chengdu, Sichuan Province, 610500, PR China
- Department of Clinical Laboratory, The Third People's Hospital of Chengdu, 82# Qinglong Street, Chengdu, Sichuan Province, 610014, PR China
| |
Collapse
|
2
|
Levy R, Le TH. Role of GSTM1 in Hypertension, CKD, and Related Diseases across the Life Span. KIDNEY360 2022; 3:2153-2163. [PMID: 36591365 PMCID: PMC9802555 DOI: 10.34067/kid.0004552022] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 10/17/2022] [Indexed: 12/31/2022]
Abstract
Over 20 years after the introduction of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, CKD remains a major public health burden with limited therapeutic options to halt or slow kidney disease progression at all ages. The consensus is that oxidative stress contributes to CKD development and progression. Yet, to date, there is no clear evidence that broad use of antioxidant therapy provides a beneficial effect in CKD. Understanding the specific pathophysiologic mechanisms in those who are genetically most susceptible to oxidative stress is a crucial step to inform therapy in an individualized medicine approach, considering differing exposures and risks across the life span. Glutathione-S-transferase μ 1 (GSTM1) is a phase 2 enzyme involved in inactivation of reactive oxygen species and metabolism of xenobiotics. In particular, those with the highly prevalent GSTM1 null genotype (GSTM1[0/0]) may be more susceptible to kidney disease progression, due to impaired capacity to handle the increased oxidative stress burden in disease states, and might specifically benefit from therapy that targets the redox imbalance mediated by loss of the GSTM1 enzyme. In this review, we will discuss the studies implicating the role of GSTM1 deficiency in kidney and related diseases from experimental rodent models to humans, from the prenatal period through senescence, and the potential underlying mechanism.
Collapse
Affiliation(s)
- Rebecca Levy
- Division of Nephrology, Department of Medicine, University of Rochester Medical Center, Rochester, New York
| | - Thu H. Le
- Division of Nephrology, Department of Medicine, University of Rochester Medical Center, Rochester, New York
| |
Collapse
|